I-Corps Teams: Development of Noninvasive Diabetes Breath Sensors

这个i-Corps项目的更广泛的影响/商业潜力是实现非侵入性、简单和便携的从人体呼吸监测血糖水平。该项目将为研究生提供商业化培训，并加强学生对商业化技能的学习。作为一项潜在的社会影响，这项创新将通过使用非侵入性呼吸传感器来识别糖尿病患者的血糖水平，从而提高生活质量。新的发现将通过演讲、研讨会、合作伙伴关系和潜在的技术转让传播给一家初创公司。来自不同公司的行业合作者将帮助将这一创新转化为工程实践。在采访过程中，100多人将被问及非侵入性糖尿病传感器的创新。这个i-Corps项目旨在为将一种用于检测呼气中丙酮的非侵入性呼吸生物传感器商业化而进行市场分析和客户采访，以识别人类的血糖水平。分子印迹层允许特定的分子暴露在传感器中，从而提高了传感器的选择性。丙酮印迹传感器在0-10ppm的范围内与丙酮浓度的增长呈广泛的线性关系，灵敏度约为15ppm/ppm。与市场上现有的糖尿病传感器相比，该传感器具有以下优势。该传感器对丙酮具有0.9ppm至10ppm的线性气体响应，可准确检测糖尿病患者呼气中的丙酮浓度(通常为1.7ppm至3.7ppm)。该传感器对水分、乙醇等不同气体分子中的丙酮具有高稳定性、高选择性和高灵敏度。该传感器体积小，可以放在口袋里。糖尿病患者可以方便而独立地携带传感器，实时检测呼气中的丙酮，以识别人体血糖水平，并帮助确定患者需要S胰岛素。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project to enable a non-invasive, simple and portable monitoring blood glucose levels from human breath. This project will provide the commercialization training to graduate students and enhance students learning on commercialization skills. As a potential societal impact, this innovation will enhance the quality of life, by using noninvasive breath sensors for the recognition of human blood glucose level for diabetics. New discoveries will be disseminated through presentations, workshops, partnerships, and potential technology transfer to a start-up company. Industrial collaborators from various companies will help translate this innovation into engineering practice. More than 100 people will be outreached about the innovations in the noninvasive diabetes sensors during the interview process.This I-Corps project is to conduct market analysis and customer interviews for commercializing a noninvasive breath biosensor for detecting acetone in exhaled breath for the recognition of human blood glucose level. The molecular imprinted layer improved the selectivity of the sensors by allowing the specific molecule to be exposed into the sensor. The acetone-imprinted sensor shows a wide range of linear relationship with the growth of the acetone concentrations in the range of 0-10 ppm at a sensitivity about 15 Ω/ppm. This sensor has the following advantages over the existing diabetes sensors in the market. This sensor has a linear gas response to acetone from 0.9 ppm to 10 ppm, which leads to accurate detection of acetone concentration in breath of patients with diabetes (usually in the range of 1.7 ppm to 3.7 ppm). This sensor demonstrates high stability, improved selectivity, and high sensitivity for acetone from different gas molecules such as moisture, ethanol, etc. This sensor has a small size that can fit in a pocket. Patients with diabetes can conveniently and discretely carry the sensor for real-time detection of acetone in exhaled breath to recognize human blood glucose level and help determine a patient?s insulin needs.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.